Answers are grounded in this paper and cite their sources.
This review uncovers disparities in cellular therapies for relapsed/refractory DLBCL, suggesting the need for improved access and utilization.
Disparities in access and utilization of autoSCT including age, sociodemographic factors, and type of treatment center, and are often intertwined. The impact of financial costs of autoSCT are significant for patients and caregivers. This review underscores persistent disparities in cellular therapies for R/R DLBCL. We must identify these disparities and implement change to improve access and utilization of these potentially curative therapies.
No takes yet. Share an insight, caveat, or question.
Esteghamat et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: